BIOSPAIN 2026

BIOSPAIN 2026

The leading biotechnology event in Southern Europe BIOSPAIN 2026 will be celebrated annually as of this year. This edition will be held in the Bilbao Exhibtion Centre from 29th September to 1st October 2026.

The event gathers companies, investors, institutions and professionals from across the global biotech ecosystem

The official BIOSPAIN 2026 website is now live, and delegate registration is open, along with the sale of exhibition spaces. Companies interested in showcasing their capabilities, strengthening their visibility and connecting with key stakeholders can now secure their booth and register attendees at the discounted early bird rates.

Last year’s edition confirmed the scale and impact of BIOSPAIN, with 2,400 registered attendees from 34 countries , +1,000 organisations, 140 investors from 76 diferent investmet firms, and 4,500 one-to-one meetings through the partnering platform.

BIOSPAIN 2026 will once again combine:

  • An international partnering platform with 30 minute on-site meetings.
  • A high-level conference agenda covering science, investment and innovation.
  • Multiple visibility and sponsorship opportunities, tailored to different strategic objectives.
  • Talent Day, a dedicated space connecting companies with biotech professionals and future talent.
  • Networking events where we combine fun with business.

Please, stay tuned for more information on the programme, speakers and activities which will be released in the coming months.

Register early and secure your place at BIOSPAIN 2026!

See you in Bilbao!


BioRN members receive a 10 % discount on ticket prices.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]

Cells Have an Early-Warning System for Stress in Mitochondria

Cells Have an Early-Warning System for Stress in Mitochondria

Internal protective mechanism responds to the very first signs of mitochondrial dysfunction Mitochondria – the powerhouses of the cell – have their own monitoring system that detects oxidative stress at a very early stage. It activates protective mechanisms even before the damage caused by this stress can spread to the rest of the cell. This […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp